Megan Baierlein
T-knife Therapeutics
CEO
Megan Baierlein is the Chief Operating Officer at T-knife Therapeutics. She brings 20 years of experience in the biotech industry where she has held senior roles in portfolio planning, program and alliance management, and clinical operations. Her experience has been gained in a range of therapeutic areas, with a focus on orphan diseases, neurology, and oncology. Megan joined T-knife from Audentes Therapeutics where she most recently served as Chief Operating Officer, overseeing program management, clinical operations, and the general and administrative functions of the company.
Previously Ms. Baierlein served as Executive Director, Program Management at Ultragenyx Pharmaceutical Inc. from 2013 through 2018. From 2009 through 2013, Ms. Baierlein held management positions at BioMarin in both program management and clinical operations. Earlier in her career, Ms. Baierlein held roles of increasing responsibility at Genentech, Inc and Elan Pharmaceuticals. Ms. Baierlein holds an B.S. in Biology and Kinesiology from the University of Minnesota.
Previously Ms. Baierlein served as Executive Director, Program Management at Ultragenyx Pharmaceutical Inc. from 2013 through 2018. From 2009 through 2013, Ms. Baierlein held management positions at BioMarin in both program management and clinical operations. Earlier in her career, Ms. Baierlein held roles of increasing responsibility at Genentech, Inc and Elan Pharmaceuticals. Ms. Baierlein holds an B.S. in Biology and Kinesiology from the University of Minnesota.